This makes it easier to make mindful choices without feeling deprived
As it stands now, the FDA has approved only two GLP-1 drugs for obesity in kids: liraglutide and semaglutide, with use restricted in both to age 12 or above
Alternative to surgery in some cases: For individuals hoping to avoid surgery (e.g., for tendon repair, ligament injury), the stack is sometimes promoted as a less invasive option, though this claim is based mostly on animal data and anecdotes
Addressing the root causes of depletion can often make your supplementation more effective
A few of the more common birth defects this drug can cause are hearing and visual impairment, missing or malformed earlobes, facial dysmorphism, and abnormalities in brain function
In 2023, the Arkansas Division of Employee Benefits explored, but ultimately decided against, providing coverage of GLP-1 therapies for weight loss for Arkansas state and public school employees